In vitro skin permeation enhancement of sumatriptan by microneedle application

Current Drug Delivery

Volumn 12, Issue 6, 2015, Pages 761-769

  Nalluri, Buchi N ^a   Anusha, Sai Sri V ^a   Bramhini, Sri R ^a   Amulya, J ^a   Sultana, Ashraf S K ^a   Teja, Chandra U ^a   Das, Diganta B ^b  

^a KVSR SIDDHARTHA COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b LOUGHBOROUGH UNIVERSITY   (United Kingdom)

Author keywords

Microneedle arrays; Microneedle rollers; Permeation; RP HPLC; Sumatriptan; Transdermal delivery

Indexed keywords

MACROGOL; PROPYLENE GLYCOL; SODIUM CHLORIDE; SUMATRIPTAN SUCCINATE; MACROGOL DERIVATIVE; SEROTONIN 1 AGONIST; SUMATRIPTAN;

ANIMAL TISSUE; APPARENT PERMEABILITY; ARTICLE; CONTROLLED STUDY; DENSITY; DIFFUSION COEFFICIENT; DRUG PENETRATION; DRUG SOLUBILITY; FORCE; HISTOPATHOLOGY; IN VITRO STUDY; MICRONEEDLE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; CUTANEOUS DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; METABOLISM; NEEDLE; PERMEABILITY; PIG; SKIN; SKIN ABSORPTION; SOLUBILITY;

ADMINISTRATION, CUTANEOUS; ANIMALS; DRUG DELIVERY SYSTEMS; NEEDLES; PERMEABILITY; POLYETHYLENE GLYCOLS; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SKIN; SKIN ABSORPTION; SOLUBILITY; SUMATRIPTAN; SWINE;

EID: 84939842201     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201812666150304123150     Document Type: Article

References (43)

1. Haut, S.R.; Bigal, M.E.; Lipton, R.B. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol., 2006, 5, 148-157.
2. Stovner, L.J.; Zwart, J.A.; Hagen, K.; Terwindt, G.M.; Pascual, J. Epidemiology of headache in Europe. Eur. J. Neurol., 2006, 13, 333-345.
3. Aliasghar, M.; Masoud, M.; Nasim, V.; Reza, H.M.; Taghi, J.M. Effect of NOS3 gene polymorphism on response to Tricyclic antidepressants in migraine attacks. Iran. J. Neurol., 2014, 13(3), 154-159.
4. Nappi, G. Introduction to the new International Classification of Headache Disorders. J. Headache Pain., 2005, 6(4), 203-204.
5. Vikelis, M.; Mitsikostas, D.D.; Alan, M.R. Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. Neuropsychiatr. Dis. Treat., 2012, 8, 429-34.
6. Steven, S.J.; Carol, O.N.; Louise, M.D.; Peter, K.; Russell M.; David, J.; Terri, S. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan succinate. Pharm. Res., 2007, 24(10), 1919-26.
7. Hansen, P.T.; De Vries, P.; Saxena, P.R. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs, 2000, 60(6), 1259-87.
8. Loder, E. Triptan therapy in migraine. N. Engl. J. Med., 2010, 363, 63-70.
9. Juhasz, G.; Zsombok, T.; Jakab, B.; Nemeth, J.; Szolcsanyi, J.; Bagdy, G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia, 2005, 25(3), 179-83.
10. Bartleson, J.D.; Cutrer, F.M. Migraine update. Diagnosis and treatment. Minn. Med., 2010, 93(5), 36-41.
11. Johnston, M.M.; Rapoport, A.M. Triptans for the management of migraine. Drugs, 2010, 70(12), 1505-18.
12. Balaguer, F.C.; Femina, F.A.; Del, R.S.; Merino, V.; Lopez, C.A. Sumatriptan Succinate Transdermal Delivery Systems for the Treatment of Migraine. J. Pharm. Sci., 2008, 97(6), 2012-9.
13. Aurora, S.; Kori, S.; Barrodale, P.; Nelsen, A.; McDonald, S. Gastric stasis occurs spontaneous, visually induced, and interictal migraine. Headache, 2007, 47, 1443-1446.
14. Boyle, R.; Behan, P.O.; Sutton, J.A. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br. J. Clin. Pharmacol., 1980, 30, 405-409.
15. Maas, H.J.; Spruit, M.A.; Danhof, M.; Della Pasqua, O.E. Relevance of absorption rate and lag time to the onset of action in migraine. Clin. Pharmacokinet., 2008, 47, 139-146.
16. Dahlof, C. Integrating the triptans into clinical practice. Curr. Opin. Neurol., 2002, 15, 317-322.
17. Dahlöf, C.G. Non-oral formulations of triptans and their use in acute migraine. Curr. Pain Headache. Rep., 2005, 9, 206-212.
18. Brian, W. B. Dermatological formulations: Percutaneous absorption, Marcel Dekker: New York, 1983. Barry, B.W. Properties that influence percutaneous absorption. In: Dermatological formulations: percutaneous absorption. Editor: Barry BW. New York: Marcel Dekker, 1983, 181-2.
19. Chien, Y.W. Transdermal controlled systemic medications, 1st ed.; Marcel Dekker: New York, 1987.
20. Sonal, R.P.; Hui, Z.; Ashutosh, S.; Yogeshvar, N.K. Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo. Eur. J. Pharm. Biopharm., 2009, 72, 304-309.
21. Balaguer, F.C.; Padula, C.; Femina, F.A.; Merino, V.; Santi, P.; López, C.A. Development and evaluation of occlusive systems employing polyvinyl alcohol for transdermal delivery of sumatriptan succinate. Drug Del., 2010, 17(2), 83-91
22. Yukako, I.; Sumie, K.; Keizo, F. Two Layered Dissolving Microneedle for Percutaneous Delivery of Sumatriptan in Rats. Drug. Dev. Ind. Pharm., 2011, 37(12), 1387-93.
23. Brychtova, K.; Dvorakova, L.; Opatrilova, R.; Raich, I.; Kacerova, S.; Placek, L.; Kalinowski, D.S., Richardson, D.R., Jampliek, J. Investigation of substituted 6-aminohexanoates as skin penetration enhancers. Bioorg. Med. Chem., 2012, 20(1), 86-5.
24. Williams, A.C.; Barry, B.W. Penetration enhancers. Adv. Drug Del. Rev., 2004, 56 (5), 603-18.
25. Wang, Y.; Thakur, R.; Fan, Q.; Michniak, B. Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. Eur. J. Pharm. Biopharm., 2005, 60(2), 170-91.
26. Gomaa, Y.A.; Garland, M.J.; McInnes, F.J.; Donnelly, R.F.; El-Khordagui, L.K.; Wilson, C.G. Flux of ionic dyes across microneedle-treated skin: Effect of molecular characteristics. Int. J. Pharm., 2012, 438 (1-2), 140-9.
27. Cheung, K.; Han, T.; Das, D.B. Effect of Force of Microneedle Insertion on the Permeability of Insulin in Skin. J. Diabetes. Sci. Technol., 2014, 8(3), 1-9.
28. Liu, S.; Jin, M.N.; Quan, Y.S.; Kamiyama, F.; Kusamori, K.; Katsumi, H.; Sakane, T.; Yamamoto, A. Transdermal delivery of relatively high molecular weight drugs using novel self-dissolving microneedle arrays fabricated from hyaluronic acid and their characteristics and safety after application to the skin. Eur. J. Pharm. Biopharm., 2014, 86(2), 267-76.
29. Gasem, K.A.M.; Yerramsetty, K.M.; Rachakonda, V.K.; Neely, B.J.; Madihally, S.V. Effect of Different Enhancers on the Transdermal Permeation of Insulin Analog. Int. J. Pharm., 2010, 398(1-2), 83-92.
30. Ita, K.; Hatsakorzian, N.; Tolstikov, V. Microneedle-Mediated Delivery of Atenolol and Bisoprolol Hemifumarate. J. Nanopharm. Drug. Deliv., 2013, 1(1), 38-44.
31. Al Qallaf, B.; and Das, D.B. Optimizing microneedle arrays for transdermal drug delivery: Extension to non-square distribution of microneedles. J. Drug Target., 2009, 17(2), 108-122.
32. Olatunji, O.; Das, D.B.; Garland, M.J.; Belaid, L.; Donnelly, R.F. Influence of array interspacing on the force required for successful microneedle skin penetration: Theoretical and practical approaches. J. Pharm. Sci., 2013, 102(4), 1209-1221.
33. Firdose, S.K.; Bramhini, R.S.; Anusha, V.S.S.; Padmini, V.L.; Buchi, N.N. Development and validation of RP-HPLC-PDA method for the analysis of sumatriptan in in vitro transdermal permeation studies. J. Chem. Pharm. Res., 2013, 5(11), 450-6.
34. Redkar, M.; Hassan, P.A.; Aswal, V.; Devarajan, P. Onion phases of PEG-8 distearate. J. Pharm. Sci., 2007, 96(9), 2436-45.
35. Boudry, I.; Blanck, O.; Cruz, C.; Blanck, M.; Vallet, V.; Bazire, A.; Capt, A.; Josse, D.; Lallement G. Percutaneous penetration and absorption of parathion using human and pig skin models in vitro and human skin grafted onto nude mouse skin model in vivo. J. Appl. Toxicol., 2008, 28(5), 645-57.
36. Bhatia, K.S.; Singh, J. Pig Ear Skin as a Model for Predicting Percutaneous Absorption in Man. Pharm. Pharmacol. Commun., 1996, 2(6), 275-276.
37. Dick, I.P.; Scott, R.C. Pig ear skin as an in vitro model for human skin permeability. J. Pharm. Pharmacol., 1992, 44, 640-645.
38. Babita, K.; Kumar, V.; Rana, V.; Jain, S.; Tiwary, A.K. Thermotropic and Spectroscopic Behavior of Skin: Relationship with Percutaneous Permeation Enhancement. Curr. Drug. Deliv., 2006, 3, 95-113.
39. Smith, W.P.; Christensen, M.S.; Nacht, S.; Gans, E.H. Effect of lipids on the aggregation and permeability of human stratum corneum. J. Invest. Dermatol., 1982, 78(1), 7-11.
40. Tojo, K.; Chiang, C.C.; Chien, Y.W. Influence of donor solution up on skin permeation of drugs. J. Chem. Eng. Jpn., 1986, 19, 153-155.
41. Watkinson, A.C.; Joubin, H.; Hadgraft, J. The influence of vehicle on permeation from saturated solutions. Intl. J. Pharm., 1995, 121, 27-36.
42. Gomaa, Y.A.; Morrow, D.I.; Garland, M.J.; Donnelly, R.F.; El-Khordagui, L.K.; Meidan, V.M. Effects of microneedle length, density, insertion time and multiple applications on human skin barrier function: assessments by transepidermal water loss. Toxicol. In Vitro, 2010, 24(7), 1971-1978.
43. Zhou, C.P.; Liu, Y.L.; Wang, H.L.; Zhang, P.X.; Zhanq, J.L. Transdermal delivery of insulin using microneedle rollers in vivo. Int. J. Pharm., 2010, 392(1-2), 127-133.